Docosahexaenoic acid (dha)    (DrugBank: Docosahexaenoic acid)

3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病1
94原発性硬化性胆管炎1
299嚢胞性線維症2

6. パーキンソン病 [臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,123 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01563913
(ClinicalTrials.gov)
October 201216/3/2012Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty AcidsReducing Dyskinesia in Parkinson Disease With Omega-3 Fatty AcidsParkinson's DiseaseDrug: Docosahexaenoic Acid (DHA);Drug: PlaceboVA Office of Research and DevelopmentOregon Health and Science UniversityCompleted21 Years99 YearsAll33Phase 1United States

94. 原発性硬化性胆管炎 [臨床試験数:134,薬物数:105(DrugBank:37),標的遺伝子数:18,標的パスウェイ数:131
Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 134 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00325013
(ClinicalTrials.gov)
December 200510/5/2006Evaluation of DHA for the Treatment of PSCEvaluation of Docosahexaenoic Acid (DHA) for the Treatment of Primary Sclerosing Cholangitis (PSC)Primary Sclerosing Cholangitis;ColitisDrug: Docosahexaenoic Acid (DHA)Beth Israel Deaconess Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed18 Years80 YearsBoth10Phase 1United States

299. 嚢胞性線維症 [臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 1,592 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-020516-11-IT
(EUCTR)
16/09/201028/09/2010EXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - NDEXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - ND CYSTIC FIBROSIS AND PANCREATIC INSUFFICIENCY
MedDRA version: 9.1;Level: PT;Classification code 10033628
MedDRA version: 9.1;Classification code 10011762
Trade Name: PREFOLIC*30CPR GASTROR 15MG
INN or Proposed INN: Detoxifying agents for antineoplastic treatment
Trade Name: INDUSIL*OS GTT FL 30MG+FL 15ML
INN or Proposed INN: Cobamamide
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
2NCT00530244
(ClinicalTrials.gov)
March 200313/9/2007Use of Formula Fortified With DHA in Infants With Cystic FibrosisThe Effect of Formula Fortified With Docosahexaenoic Acid (DHA) on Infants With Cystic Fibrosis (CF)Cystic FibrosisDietary Supplement: Docosahexaenoic acid (DHA);Dietary Supplement: Standard formula (Enfamil)University of Massachusetts, WorcesterCystic Fibrosis FoundationCompletedN/A56 DaysAll76N/AUnited States